Nevertheless, the present study exposed that concurrent blockade of the glutamine transporter alanine‐serine‐cysteine type 2 (ASCT2, encoded by SLC1A5) and GLS1 could generate significant anti‐tumor activity with a manageable safety profile. This evidence concerns the gene GLS and neoplasm.